Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions
IntroductionAntibody-drug conjugates (ADCs) have emerged as a transformative therapeutic modality in oncology, offering unprecedented precision in targeting tumor cells while sparing healthy tissues. In bladder cancer, a malignancy with high recurrence rates and limited treatment options, ADCs have...
Saved in:
| Main Authors: | Fei Zhang, Sheng Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1591191/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody-drug conjugates in cancer therapy: applications and future advances
by: Rou Long, et al.
Published: (2025-05-01) -
Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024-11-01) -
Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01) -
Diverse Roles of Antibodies in Antibody–Drug Conjugates
by: Aiko Yamaguchi, et al.
Published: (2025-01-01) -
Clinical advances in antibody-drug conjugates for hematological malignancies
by: TANG Sijie, et al.
Published: (2024-12-01)